Literature DB >> 21536505

An LC-MS/MS procedure for the quantification of naproxen in human plasma: development, validation, comparison with other methods, and application to a pharmacokinetic study.

Paul W Elsinghorst1, Martina Kinzig, Michael Rodamer, Ulrike Holzgrabe, Fritz Sörgel.   

Abstract

A sensitive, precise and accurate quantitative LC-MS/MS method for the measurement of naproxen in human plasma was developed and completely validated according to current FDA and EMA guidelines. The new method employs acetonitrile protein precipitation for sample preparation and uses ketoprofen as the internal standard. Suitability of the new assay was assessed in comparison with 36 reported bioanalytical assays and the pharmacokinetic results obtained by the new method were compared to 11 reported studies in humans. The principal advantage of this LC-MS/MS method is the simultaneous achievement of high absolute recovery (90.0±3.6%), acceptable sensitivity (lower limit of quantitation of 0.100 μg/mL), high inter-day precision (CV≤9.4%), high analytical recovery (between 94.4 and 103.1%), and excellent linearity over the concentration range 0.100-50.0 μg/mL (r(2)≥0.998) combined with a short run time of only 2 min.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536505     DOI: 10.1016/j.jchromb.2011.04.012

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

2.  Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.

Authors:  Ronald A Lubet; James M Scheiman; Ann Bode; Jonathan White; Lori Minasian; M Margaret Juliana; Daniel L Boring; Vernon E Steele; Clinton J Grubbs
Journal:  Cancer Prev Res (Phila)       Date:  2015-03-11

3.  Physicochemical, pharmacokinetics, and histological evaluation of new naproxen-quercetin co-lyophilizate to diminish drug-induced gastric irritations in rats.

Authors:  Mohamed Abbas Ibrahim; Gamal A Shazly; Gehan M Elossaily; Essam Ezzeldin; Fadilah S Aleanizy
Journal:  Saudi Pharm J       Date:  2019-01-08       Impact factor: 4.330

4.  No apparent effect of naproxen on CSF markers of innate immune activation.

Authors:  Pierre-François Meyer; Anne Labonté; Pedro Rosa-Neto; Judes Poirier; John C S Breitner
Journal:  Ann Clin Transl Neurol       Date:  2019-06-06       Impact factor: 4.511

5.  Oleacein Intestinal Permeation and Metabolism in Rats Using an In Situ Perfusion Technique.

Authors:  Anallely López-Yerena; Maria Pérez; Anna Vallverdú-Queralt; Eleftherios Miliarakis; Rosa M Lamuela-Raventós; Elvira Escribano-Ferrer
Journal:  Pharmaceutics       Date:  2021-05-14       Impact factor: 6.321

6.  The RP-HPLC method for simultaneous estimation of esomeprazole and naproxen in binary combination.

Authors:  Deepak Kumar Jain; Nitesh Jain; Rita Charde; Nilesh Jain
Journal:  Pharm Methods       Date:  2011-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.